Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$14.91
+3.9%		$14.77
$10.05
▼
$17.35
$25.97B0.08106,842 shs124,619 shs
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$19.97
+3.8%		$20.94
$18.33
▼
$34.84
$63.33B0.6336,369 shs547,052 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.06
+2.5%		$49.68
$42.85
▼
$61.69
$96.83B0.335.27 million shs6.14 million shs
Sanofi stock logo
SNY
Sanofi
$40.29
+1.3%		$42.74
$39.07
▼
$52.68
$96.42B0.333.34 million shs5.05 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
+3.90%+5.00%+0.34%+12.27%+42.41%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
+3.79%+4.01%-3.90%-11.68%-14.77%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+2.37%+5.46%-1.90%-5.31%+11.99%
Sanofi stock logo
SNY
Sanofi
+1.31%+0.15%-4.98%-9.79%-17.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$14.91
+3.9%		$14.77
$10.05
▼
$17.35
$25.97B0.08106,842 shs124,619 shs
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$19.97
+3.8%		$20.94
$18.33
▼
$34.84
$63.33B0.6336,369 shs547,052 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.06
+2.5%		$49.68
$42.85
▼
$61.69
$96.83B0.335.27 million shs6.14 million shs
Sanofi stock logo
SNY
Sanofi
$40.29
+1.3%		$42.74
$39.07
▼
$52.68
$96.42B0.333.34 million shs5.05 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
+3.90%+5.00%+0.34%+12.27%+42.41%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
+3.79%+4.01%-3.90%-11.68%-14.77%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+2.37%+5.46%-1.90%-5.31%+11.99%
Sanofi stock logo
SNY
Sanofi
+1.31%+0.15%-4.98%-9.79%-17.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
2.50
Moderate BuyN/AN/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
2.60
Moderate BuyN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.05
Hold$55.3312.79% Upside
Sanofi stock logo
SNY
Sanofi
2.38
Hold$49.5022.86% Upside

Current Analyst Ratings Breakdown

Latest ALPMY, GSK, SNY, and CHGCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$70.00
10/9/2026
Sanofi stock logo
SNY
Sanofi
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoveragePeer Perform
10/8/2026
Sanofi stock logo
SNY
Sanofi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Sell (D+)
10/6/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
Sanofi stock logo
SNY
Sanofi
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/1/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell
10/1/2026
Sanofi stock logo
SNY
Sanofi
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/1/2026
Sanofi stock logo
SNY
Sanofi
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
9/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
9/29/2026
Sanofi stock logo
SNY
Sanofi
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$14.21B1.90$2.32 per share6.42$6.36 per share2.34
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$8.41B7.81$0.98 per share20.29$4.12 per share4.85
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.30$6.16 per share7.97$10.32 per share4.75
Sanofi stock logo
SNY
Sanofi
$49.35B1.98$7.16 per share5.63$33.27 per share1.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$1.83B$1.318.5911.30N/A16.01%25.79%12.87%11/4/2026 (Estimated)
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$2.91B$0.9220.9116.24N/A35.09%23.76%19.92%10/23/2026 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2015.349.812.1514.56%43.23%11.60%10/28/2026 (Estimated)
Sanofi stock logo
SNY
Sanofi
$8.84B$1.9121.097.761.228.66%14.19%7.95%10/30/2026 (Estimated)

Latest ALPMY, GSK, SNY, and CHGCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026N/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.3990N/AN/AN/A$3.80 billionN/A
10/30/2026Q3 2026
Sanofi stock logo
SNY
Sanofi
$1.63N/AN/AN/A$15.33 billionN/A
10/28/2026Q3 2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.32N/AN/AN/A$11.73 billionN/A
7/30/2026Q2 2026
Sanofi stock logo
SNY
Sanofi
N/A$2.41N/A$0.17N/A$13.36 billion
7/28/2026Q2 2026 & Strategy update
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.27$1.36+$0.09$0.28$11.02 billion$11.14 billion
7/24/2026Q2 2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A$0.22N/A$0.22$2.38 billion$2.14 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.291.95%N/A22.14%N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$0.251.25%N/A27.17%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.773.61%-7.86%55.31%N/A
Sanofi stock logo
SNY
Sanofi
$1.764.37%+6.46%92.15%N/A

Latest ALPMY, GSK, SNY, and CHGCY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.65%8/14/20268/14/202610/8/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.16
1.20
0.93
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
4.35
3.54
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52
Sanofi stock logo
SNY
Sanofi
0.21
0.99
0.64

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
0.01%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Sanofi stock logo
SNY
Sanofi
14.03%

Insider Ownership

CompanyInsider Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,0991.81 billionN/ANot Optionable
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
7,8723.29 billionN/ANot Optionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable

Recent News About These Companies

Recursion To Receive $10 Mln Milestone Payment As Sanofi Selects Immunology Drug Candidate
October 15 at 12:24 PM  |  rttnews.comhttps://www.rttnews.com/3699473/recursion-to-receive-10-mln-milestone-payment-as-sanofi-selects-immunology-drug-candidate.aspx
Recursion announces $200M equity offering, Sanofi milestone
October 15 at 12:24 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4653372-recursion-wins-200m-investment-sanofi-milestone
Sanofi set October 30 results date as Sanofi stock trades at EUR 70.80
October 14 at 10:45 PM  |  ad-hoc-news.deA
European Commission Accepts Makes Sanofi's Commitments Legally Binding On Flu Vaccine Practices
October 14 at 10:45 PM  |  rttnews.comhttps://www.rttnews.com/3698965/european-commission-accepts-makes-sanofi-s-commitments-legally-binding-on-flu-vaccine-practices.aspx
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
October 14 at 1:11 PM  |  zacks.comhttps://www.zacks.com/stock/news/3007283/which-pharma-stock-looks-more-attractive-sanofi-or-abbvie?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3007283
Update: European Commission Accepts Sanofi's Offer to Address Potential Anticompetitive Disparagement of Competing Flu Vaccine
October 14 at 7:26 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/european-commission-accepts-sanofi-apos-100018940.html
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
October 14 at 4:26 AM  |  wsj.comhttps://www.wsj.com/business/eu-accepts-sanofis-concessions-to-settle-antitrust-probe-over-vaccine-marketing-a07a2a95
Sanofi Falls to $39.12, Breaking Its Year-Long Price Floor
October 13 at 10:48 PM  |  247wallst.comhttps://247wallst.com/cards/sanofi-cut-a-new-52-week-low-at-39-12-undercutting-its-oct-sny-price-extreme-01m4vtkvee5xsx6s19wh7hbmxy
Sanofi (NASDAQ:SNY) Sets New 1-Year Low - What's Next?
October 13 at 3:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sanofi-nasdaq-sny-sets-new-1-year-low-whats-next-2026-10-13/
Wolfe Research Initiates Coverage on Sanofi (NASDAQ:SNY)
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106833
Wolfe Research Begins Coverage on Sanofi (NASDAQ:SNY)
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wolfe-research-begins-coverage-on-sanofi-nasdaq-sny-2026-10-09/
Press Release : Availability of the aide-mémoire for Q3 2026 results
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375120/0/en/press-release-availability-of-the-aide-m%c3%a9moire-for-q3-2026-results.html
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
October 5, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/05/novavax-soars-22-as-sanofi-carries-nuvaxovid-into-vaccination-season-moderna-climbs-8-biontech-ticks-up/?utm_source=snapi
Wall Street Zen Downgrades Sanofi (NASDAQ:SNY) to Hold
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-downgrades-sanofi-nasdaq-sny-to-hold-2026-10-03/
Sanofi (NASDAQ:SNY) Hits New 12-Month Low - Here's Why
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sanofi-nasdaq-sny-hits-new-12-month-low-heres-why-2026-10-02/
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
October 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999440/sanofi-regeneron-expand-immunology-alliance-with-new-antibodies?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2999440
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
October 1, 2026  |  webwire.comW
Sanofi (SNY) Stock Gains Following Massive $8B Regeneron Partnership Expansion
October 1, 2026  |  moneycheck.comM
Regeneron, Sanofi expand immunology alliance with $1B upfront payment: Here are the key highlights
October 1, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/regeneron-sanofi-expand-immunology-alliance-with-1b-upfront-payment-here-are-the-key-highlights/ar-AA2dlATz
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-sanofi-regeneron-expand-dupixent-alliance-in-deal-worth-up-to-8-billion-2026-10-01/
Sanofi, Regeneron Expand Immunology Partnership in $1 Billion Deal
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sanofi-regeneron-expand-immunology-partnership-075335028.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$14.91 +0.56 (+3.90%)
As of 10/15/2026 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Chugai Pharmaceutical stock logo

Chugai Pharmaceutical OTCMKTS:CHGCY

$19.97 +0.73 (+3.79%)
As of 10/15/2026 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

GSK stock logo

GSK NYSE:GSK

$49.06 +1.19 (+2.48%)
Closing price 10/15/2026 03:59 PM Eastern
Extended Trading
$49.35 +0.29 (+0.59%)
As of 10/15/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi stock logo

Sanofi NASDAQ:SNY

$40.29 +0.52 (+1.31%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$40.28 -0.01 (-0.01%)
As of 10/15/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas